After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...

Havas Health Network has rebranded a U.K. agency. Havas Life Medicom is now Havas Life London, a group focused on brand, ...

In 2024, the pharma industry found itself with a growing “trust paradox.” While innovations like gene therapies and rare ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some safety setbacks and years of generic competition, Takeda is calling it quits ...

By August or September of this year, Petersen said he expects “basically half” of the company’s $8 billion in manufacturing investments to be “in operation,” calling 2025 the “biggest year” yet for ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...